ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Other Events
Item 8.01 Other Events.
titled “Acceleron Announces Top-line Results from DART Phase 2
Study of Dalantercept in Advanced Renal Cell Carcinoma.”
Current Report on Form 8-K and is incorporated herein by
reference.
|
Exhibit Number
|
Description of Exhibit
|
|
|
99.1
|
Press release of Acceleron Pharma Inc. dated June 12,
2017 |
About ACCELERON PHARMA INC. (NASDAQ:XLRN)
Acceleron Pharma Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutic candidates that are based on mechanisms, which the human body uses to regulate the growth and repair of its cells and tissues. Its therapeutic candidates are used to treat serious and rare diseases. The Company’s pipeline includes Luspatercept, Sotatercept, Dalantercept, ACE-083, ACE-2494, ACE-1332, ACE-3891, ACE-2798, ACE-2536 and ACE-2395. Luspatercept promotes red blood cell production. It is developing Sotatercept for the treatment of chronic kidney disease. Dalantercept treats cancers by inhibiting blood vessel formation by inhibiting signaling through the activin receptor-like kinase (ALK) 1 receptor. ACE-083 is for the treatment of focal muscle disorders. ACE-2494 is designed to treat systemic muscle disorders. ACE-3891, ACE-1332, ACE-2798, ACE-2536 and ACE-2395 are in preclinical stage of development.
